Intellia Therapeutics Financial Statements (NTLA)
|
|
|
|
Report date
|
|
|
27.02.2020 |
26.02.2021 |
24.02.2022 |
23.02.2023 |
22.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
43.1 |
58.0 |
33.1 |
52.1 |
36.3 |
|
46.9 |
|
Operating Income, bln rub |
|
|
-106.4 |
-136.6 |
-267.9 |
-458.2 |
-515.3 |
|
-537.7 |
|
EBITDA, bln rub |
? |
|
-100.8 |
-130.3 |
-261.0 |
-450.6 |
-506.3 |
|
-527.5 |
|
Net profit, bln rub |
? |
|
-92.7 |
-125.6 |
-259.7 |
-490.2 |
-481.2 |
|
-522.3 |
|
|
OCF, bln rub |
? |
|
-103.2 |
-49.9 |
-225.0 |
-333.3 |
-394.1 |
|
-356.7 |
|
CAPEX, bln rub |
? |
|
6.79 |
3.59 |
12.8 |
58.4 |
14.0 |
|
6.32 |
|
FCF, bln rub |
? |
|
-110.0 |
-53.5 |
-237.8 |
-391.7 |
-408.1 |
|
-363.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
149.5 |
194.6 |
300.9 |
510.3 |
551.6 |
|
575.7 |
|
Cost of production, bln rub |
|
|
108.4 |
150.4 |
6.89 |
7.57 |
435.1 |
|
7.58 |
|
R&D, bln rub |
|
|
108.4 |
150.4 |
229.8 |
420.0 |
435.1 |
|
453.3 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
8.54 |
0.000 |
|
8.83 |
|
|
Assets, bln rub |
|
|
334.3 |
676.3 |
1 294 |
1 520 |
1 301 |
|
1 173 |
|
Net Assets, bln rub |
? |
|
269.9 |
527.1 |
1 040 |
1 236 |
1 050 |
|
962.6 |
|
Debt, bln rub |
|
|
18.4 |
39.3 |
74.0 |
130.7 |
115.3 |
|
101.6 |
|
Cash, bln rub |
|
|
279.7 |
597.4 |
1 086 |
1 262 |
912.2 |
|
658.1 |
|
Net debt, bln rub |
|
|
-261.4 |
-558.1 |
-1 012 |
-1 131 |
-796.9 |
|
-556.5 |
|
|
Ordinary share price, rub |
|
|
14.7 |
54.4 |
118.2 |
34.9 |
30.5 |
|
26.5 |
|
Number of ordinary shares, mln |
|
|
47.2 |
56.0 |
70.9 |
77.0 |
88.8 |
|
101.0 |
|
|
Market cap, bln rub |
|
|
693 |
3 046 |
8 383 |
2 686 |
2 707 |
|
2 676 |
|
EV, bln rub |
? |
|
432 |
2 488 |
7 370 |
1 554 |
1 910 |
|
2 119 |
|
Book value, bln rub |
|
|
270 |
527 |
1 040 |
1 236 |
1 050 |
|
963 |
|
|
EPS, rub |
? |
|
-1.96 |
-2.24 |
-3.66 |
-6.37 |
-5.42 |
|
-5.17 |
|
FCF/share, rub |
|
|
-2.33 |
-0.96 |
-3.35 |
-5.09 |
-4.60 |
|
-3.59 |
|
BV/share, rub |
|
|
5.71 |
9.41 |
14.7 |
16.1 |
11.8 |
|
9.53 |
|
|
EBITDA margin, % |
? |
|
-233.8% |
-224.6% |
-789.5% |
-864.5% |
-1 396% |
|
-1 124% |
|
Net margin, % |
? |
|
-215.1% |
-216.5% |
-785.8% |
-940.5% |
-1 327% |
|
-1 113% |
|
FCF yield, % |
? |
|
-15.9% |
-1.76% |
-2.84% |
-14.6% |
-15.1% |
|
-13.6% |
|
ROE, % |
? |
|
-34.3% |
-23.8% |
-25.0% |
-39.7% |
-45.8% |
|
-54.3% |
|
ROA, % |
? |
|
-27.7% |
-18.6% |
-20.1% |
-32.2% |
-37.0% |
|
-44.5% |
|
|
P/E |
? |
|
-7.48 |
-24.3 |
-32.3 |
-5.48 |
-5.62 |
|
-5.12 |
|
P/FCF |
|
|
-6.30 |
-56.9 |
-35.3 |
-6.86 |
-6.63 |
|
-7.37 |
|
P/S |
? |
|
16.1 |
52.5 |
253.6 |
51.5 |
74.6 |
|
57.0 |
|
P/BV |
? |
|
2.57 |
5.78 |
8.06 |
2.17 |
2.58 |
|
2.78 |
|
EV/EBITDA |
? |
|
-4.28 |
-19.1 |
-28.2 |
-3.45 |
-3.77 |
|
-4.02 |
|
Debt/EBITDA |
|
|
2.59 |
4.28 |
3.88 |
2.51 |
1.57 |
|
1.05 |
|
|
R&D/CAPEX, % |
|
|
1 596% |
4 195% |
1 802% |
719.3% |
3 111% |
|
7 176% |
|
|
CAPEX/Revenue, % |
|
|
15.8% |
6.18% |
38.6% |
112.0% |
38.6% |
|
13.5% |
|
| Intellia Therapeutics shareholders |
